Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 362

1.

Benefit evaluation in multiple sclerosis relapse treatment from the patients' perspective - Development and validation of a new questionnaire.

Beckmann H, Augustin M, Heesen C, Poettgen J, Blome C.

Mult Scler Relat Disord. 2019 Feb;28:256-261. doi: 10.1016/j.msard.2018.12.021. Epub 2018 Dec 17.

PMID:
30639826
2.

Clinical and genetic characteristics of late-onset Huntington's disease.

Oosterloo M, Bijlsma EK, van Kuijk SM, Minkels F, de Die-Smulders CE; REGISTRY Investigators of the European Huntington's Disease Network; Registry Steering committee; Language coordinators; EHDN's associate site in Singapore.

Parkinsonism Relat Disord. 2019 Apr;61:101-105. doi: 10.1016/j.parkreldis.2018.11.009. Epub 2018 Nov 29.

PMID:
30528461
3.

A single class of ARF GTPase activated by several pathway-specific ARF-GEFs regulates essential membrane traffic in Arabidopsis.

Singh MK, Richter S, Beckmann H, Kientz M, Stierhof YD, Anders N, Fäßler F, Nielsen M, Knöll C, Thomann A, Franz-Wachtel M, Macek B, Skriver K, Pimpl P, Jürgens G.

PLoS Genet. 2018 Nov 15;14(11):e1007795. doi: 10.1371/journal.pgen.1007795. eCollection 2018 Nov.

4.

Understanding and Predicting Antidepressant Response: Using Animal Models to Move Toward Precision Psychiatry.

Herzog DP, Beckmann H, Lieb K, Ryu S, Müller MB.

Front Psychiatry. 2018 Oct 22;9:512. doi: 10.3389/fpsyt.2018.00512. eCollection 2018. Review.

5.

Reduced Cancer Incidence in Huntington's Disease: Analysis in the Registry Study.

McNulty P, Pilcher R, Ramesh R, Necuiniate R, Hughes A, Farewell D, Holmans P, Jones L; REGISTRY Investigators of the European Huntington's Disease Network.

J Huntingtons Dis. 2018;7(3):209-222. doi: 10.3233/JHD-170263.

PMID:
30103338
6.

Objective assessment of gait and posture in premanifest and manifest Huntington disease - A multi-center study.

Beckmann H, Bohlen S, Saft C, Hoffmann R, Gerss J, Muratori L, Ringelstein EB, Landwehrmeyer GB, Reilmann R.

Gait Posture. 2018 May;62:451-457. doi: 10.1016/j.gaitpost.2018.03.039. Epub 2018 Apr 7.

PMID:
29660633
7.

A benzothiadiazine derivative and methylprednisolone are novel and selective activators of transient receptor potential canonical 5 (TRPC5) channels.

Beckmann H, Richter J, Hill K, Urban N, Lemoine H, Schaefer M.

Cell Calcium. 2017 Sep;66:10-18. doi: 10.1016/j.ceca.2017.05.012. Epub 2017 Jun 2.

PMID:
28807145
8.

Differing roles for short chain fatty acids and GPR43 agonism in the regulation of intestinal barrier function and immune responses.

D'Souza WN, Douangpanya J, Mu S, Jaeckel P, Zhang M, Maxwell JR, Rottman JB, Labitzke K, Willee A, Beckmann H, Wang Y, Li Y, Schwandner R, Johnston JA, Towne JE, Hsu H.

PLoS One. 2017 Jul 20;12(7):e0180190. doi: 10.1371/journal.pone.0180190. eCollection 2017.

9.

Efficacy of standard prophylaxis versus on-demand treatment with bayer's sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A.

Zhao Y, Xiao J, Yang R, Wu R, Hu Y, Beckmann H, Wu J, Hou Q, Sun J.

Pediatr Hematol Oncol. 2017 Apr;34(3):138-148. doi: 10.1080/08880018.2017.1313921. Epub 2017 Jul 20.

PMID:
28727494
10.

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.

Moss DJH, Pardiñas AF, Langbehn D, Lo K, Leavitt BR, Roos R, Durr A, Mead S; TRACK-HD investigators; REGISTRY investigators, Holmans P, Jones L, Tabrizi SJ.

Lancet Neurol. 2017 Sep;16(9):701-711. doi: 10.1016/S1474-4422(17)30161-8. Epub 2017 Jun 20. Erratum in: Lancet Neurol. 2017 Sep;16(9):683.

PMID:
28642124
11.

Primidone inhibits TRPM3 and attenuates thermal nociception in vivo.

Krügel U, Straub I, Beckmann H, Schaefer M.

Pain. 2017 May;158(5):856-867. doi: 10.1097/j.pain.0000000000000846.

12.

Clinical manifestations of intermediate allele carriers in Huntington disease.

Cubo E, Ramos-Arroyo MA, Martinez-Horta S, Martínez-Descalls A, Calvo S, Gil-Polo C; European HD Network.

Neurology. 2016 Aug 9;87(6):571-8. doi: 10.1212/WNL.0000000000002944. Epub 2016 Jul 8.

PMID:
27402890
13.

Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial.

Saxena K, Lalezari S, Oldenburg J, Tseneklidou-Stoeter D, Beckmann H, Yoon M, Maas Enriquez M.

Haemophilia. 2016 Sep;22(5):706-12. doi: 10.1111/hae.12952. Epub 2016 Jun 24.

PMID:
27339736
14.

BAY 81-8973, a full-length recombinant factor VIII: results from an International comparative laboratory field study.

Kitchen S, Beckmann H, Katterle Y, Bruns S, Tseneklidou-Stoeter D, Maas Enriquez M.

Haemophilia. 2016 May;22(3):e192-9. doi: 10.1111/hae.12925. Epub 2016 Mar 31.

PMID:
27030173
15.

Chromogenic assay for BAY 81-8973 potency assignment has no impact on clinical outcome or monitoring in patient samples.

Kitchen S, Katterle Y, Beckmann H, Maas Enriquez M.

J Thromb Haemost. 2016 Jun;14(6):1192-9. doi: 10.1111/jth.13322. Epub 2016 May 3.

16.

Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme.

Oldenburg J, Windyga J, Hampton K, Lalezari S, Tseneklidou-Stoeter D, Beckmann H, Maas Enriquez M.

Haemophilia. 2016 May;22(3):349-53. doi: 10.1111/hae.12839. Epub 2016 Mar 1.

PMID:
26931631
17.

Spectral sensitivity in Onychophora (velvet worms) revealed by electroretinograms, phototactic behaviour and opsin gene expression.

Beckmann H, Hering L, Henze MJ, Kelber A, Stevenson PA, Mayer G.

J Exp Biol. 2015 Mar;218(Pt 6):915-22. doi: 10.1242/jeb.116780. Epub 2015 Jan 23.

18.

Unfolded Protein Response in Cancer: IRE1α Inhibition by Selective Kinase Ligands Does Not Impair Tumor Cell Viability.

Harrington PE, Biswas K, Malwitz D, Tasker AS, Mohr C, Andrews KL, Dellamaggiore K, Kendall R, Beckmann H, Jaeckel P, Materna-Reichelt S, Allen JR, Lipford JR.

ACS Med Chem Lett. 2014 Sep 24;6(1):68-72. doi: 10.1021/ml500315b. eCollection 2015 Jan 8.

19.

Discovery of 1H-pyrazol-3(2H)-ones as potent and selective inhibitors of protein kinase R-like endoplasmic reticulum kinase (PERK).

Smith AL, Andrews KL, Beckmann H, Bellon SF, Beltran PJ, Booker S, Chen H, Chung YA, D'Angelo ND, Dao J, Dellamaggiore KR, Jaeckel P, Kendall R, Labitzke K, Long AM, Materna-Reichelt S, Mitchell P, Norman MH, Powers D, Rose M, Shaffer PL, Wu MM, Lipford JR.

J Med Chem. 2015 Feb 12;58(3):1426-41. doi: 10.1021/jm5017494. Epub 2015 Jan 14.

PMID:
25587754
20.

Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II).

Kavakli K, Yang R, Rusen L, Beckmann H, Tseneklidou-Stoeter D, Maas Enriquez M; LEOPOLD II Study Investigators.

J Thromb Haemost. 2015 Mar;13(3):360-9.

Supplemental Content

Loading ...
Support Center